While patient engagement is firmly at the epicenter for health care initiatives and research efforts designed to speed the development of new cures, the American Medical Association (AMA) is reminding lawmakers that the physician voice also needs to be heard from ground zero. more »
A partnering process for a preclinical-stage asset brought together former Amgen Inc. colleagues and resulted in a deal that could accelerate the growth of low-flying biotech NGM Biopharmaceuticals Inc.
Consumers are frustrated with the pace of drug and medical device development, and they want more engagement with industry and regulators at every step of the process, from trial design to FDA review.
- 'Titer'-ing on brink of BLA, Adma's added endpoints encourage outcomes in RSV
- Orca strikes $122.5M RORγ deal with Astrazeneca
- Sunovion seeks to 'elevate' COPD treatment with LAMA candidate
- AMA: Physician voice equally important in health care transformation
- Careful planning lays foundation to restore p53 activity, combat cancer
- Patent filings up in China: What does that mean for the biopharma sector?
- China sees more than 20,000 pharma patents filed in 2013
- GPCR Consortium lands Novo Nordisk, Merck
- Cipla's challenge of Novartis' patent for COPD drug tests India's manufacturing law
- Common heart drug interactions traced to vitamin K: study
In 2011, the National Research Council (NRC) published a report, titled "Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease," which set the ball rolling on changing our current thinking about use of the term "personalized medicine." The report preferred "precision medicine" to convey a more accurate tailoring of medical treatment to the individual characteristics of each patient, not just merely a personalized approach that involved the creation of medicines that are unique to a patient.
Antioxidants seem to be on a Bill Cosby-like downward spiral from wholesomeness to villainy.
The newest accusations can be found in the Feb. 9, 2015, issue of Cancer Cell, where scientists reported that antioxidants drove both the initiation and the progression of tumors, and that blocking antioxidant pathways could destroy tumor cells.
Because they scavenge free radicals, which induce DNA damage as well as other damage in cells, antioxidants were once thought to protect against cancer.
That idea, however, has not held up to scientific scrutiny.READ MORE »
- Export inhibitors ride SINE wave into neurodegeneration »
- Nanotechnology approaches target atherosclerotic plaques »
- Common heart drug interactions traced to vitamin K: study »
- Potent breast cancer candidate targets stem, bulk tumor cells »
- Vaccines can help fight drug resistance »
- Engineered insulin knows when it's needed »
- Brain tissue growth has research, development implications, study says »
- Hepatitis-liver cancer connection may yield tailored therapies »
- Blocking new target inhibits lung cancer growth, metastasis »
- Patient engagement as important as the dataFebruary 20, 2015 | 5:50 PM | Posted by: Mari Serebrov
- Listening to the voice that mattersFebruary 04, 2015 | 3:35 PM | Posted by: Mari Serebrov
- States move forward as SEC lags on crowdfunding rulesJanuary 29, 2015 | 6:55 PM | Posted by: Michael Fitzhugh
- Old dogs and new tricks: The real-world consequences of excluding older adults from drug trialsDecember 10, 2014 | 8:14 PM | Posted by: Marie Powers
- Shoppers, start your engines: BioWorld’s 8th Annual Gift GuideDecember 01, 2014 | 6:12 PM | Posted by: Marie Powers
Partners in Focus
Cast Your Vote
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter